카지노 슬롯 머신 규칙

The once-weekly GLP-1 receptor agonist 카지노 슬롯 머신 규칙 (semaglutide) has redefined its clinical positioning by demonstrating a reduction in major adverse cardiovascular events (MACE), establishing itself as a treatment for chronic diseases rather than solely an anti-obesity drug.

On January 21, Novo Nordisk Korea hosted a specialized media session to discuss 카지노 슬롯 머신 규칙’s clinical significance following its launch in Korea on October 15.

Professor Soo Lim from Seoul National University Bundang Hospital underscored the global rise in obesity, citing projections that the number of individuals with obesity will increase from 998 million in 2020 to 1.556 billion by 2030. Concurrently, the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD), waist circumference, glycated hemoglobin (HbA1c), and triglyceride levels are rising.

He attributed this trend to high-fat diets, excessive fructose intake, and reduced physical activity, emphasizing the urgency of effective pharmacological interventions. In South Korea, adult obesity reached 38.4% in 2022, with severe obesity (BMI ≥30 kg/㎡) growing at an alarming rate. Patients with MASLD face heightened mortality risks, but 카지노 슬롯 머신 규칙 loss has proven to mitigate these risks.

Professor Lim highlighted that earlier obesity treatments like Saxenda (liraglutide) achieved only 7–8% weight reduction, whereas 카지노 슬롯 머신 규칙, introduced in 2020, demonstrated a 16.9% reduction, marking a breakthrough.

Clinical trials further validate 카지노 슬롯 머신 규칙’s efficacy. The global Phase 3 STEP 1 study, targeting adults with a BMI of at least 30 kg/㎡ or 27 kg/㎡ with weight-related comorbidities, showed that those receiving 2.4 mg of 카지노 슬롯 머신 규칙 achieved a 14.9% weight reduction over 68 weeks, compared to 2.4% in the placebo group (95% CI: -13.4 to -11.5, p<0.001). Additionally, 50.5% of the 카지노 슬롯 머신 규칙 group lost at least 15% of their body weight, compared to 4.9% in the placebo group.

In the STEP 6 study, which included 41 South Korean and 360 Japanese participants, 카지노 슬롯 머신 규칙 resulted in a 13.2% weight reduction over 68 weeks, compared to 2.1% in the placebo group (95% CI: -12.9 to -9.2, p<0.0001). Notably, 41% of the 카지노 슬롯 머신 규칙 group achieved at least 15% weight loss versus 3% in the placebo group.

The drug’s safety profile remained consistent with prior GLP-1 receptor agonist studies. The most common side effects included mild to moderate gastrointestinal symptoms such as nausea, diarrhea, vomiting, and constipation, which typically resolved without discontinuation.

Professor Lim emphasized that 카지노 슬롯 머신 규칙’s once-weekly administration offers added convenience alongside its efficacy. Beyond weight loss, it has demonstrated benefits in blood glucose control, blood pressure regulation, and inflammatory marker reduction. Given that 50% of Korean diabetes patients are obese, 60% have hypertension, 40% have kidney disease, and 70% have hypercholesterolemia, 카지노 슬롯 머신 규칙 is expected to play a key role in managing these conditions.

Professor Jong-Chan Yoon from Seoul St. Mary’s Hospital elaborated on 카지노 슬롯 머신 규칙’s role in cardiovascular risk reduction. He noted that cardiovascular disease remains a leading cause of death globally, with obesity being a significant risk factor. Data from 195 countries between 1990 and 2015 showed that two-thirds of obesity-related deaths were linked to cardiovascular disease.

Novo Nordisk’s global Phase 3 SELECT trial further examined this connection. The study enrolled adults aged 45 and older with confirmed cardiovascular disease and a BMI of at least 27 kg/m². To ensure an accurate assessment of 카지노 슬롯 머신 규칙’s cardiovascular benefits, diabetes patients were excluded.

Professor Yoon highlighted that in the SELECT study, over a mean follow-up period of 39.8 months, 카지노 슬롯 머신 규칙 reduced the risk of MACE by 20% compared to placebo (HR 0.80, 95% CI: 0.72–0.90, p<0.001). Unlike its weight loss effects, which peak after a year, its impact on MACE was evident within six months, making it particularly compelling from a cardiology standpoint. He emphasized that obesity treatment should now extend beyond weight loss to include MACE risk reduction, given the shared pathophysiology of kidney disease, cardiovascular disease, and diabetes.

Julie Broe Honore, Senior CMR Director of Novo Nordisk Korea, reaffirmed the company’s commitment to obesity research, stating, “Novo Nordisk recognizes obesity as a chronic disease linked to metabolic disorders and cardiovascular complications. For over 20 years, we have been dedicated to obesity research, ensuring the safety of 카지노 슬롯 머신 규칙. Our goal has always been to improve the overall health of individuals with obesity rather than focusing solely on weight management.”

She added that 카지노 슬롯 머신 규칙’s demonstrated reduction in MACE risk represents a major advancement in obesity treatment. Novo Nordisk will continue working with medical professionals to drive transformative changes in obesity care, enhancing both health outcomes and quality of life for patients.